AstraZeneca announced it will no longer file marketing applications in the U.S. and Europe this fall for Recentin (cediranib) in first-line metastatic colorectal cancer after the VEGF inhibitor failed to show an overall survival benefit in the Phase III HORIAON II study.
With GlaxoSmithKline's blockbuster asthma drug Advairfacing patent expiration later this year, generic drug makers like Teva and Sandoz are looking to pounce on the opportunity.
Pfizer is halting recruitment for its EMPHASIS-HF trial early after an interim analysis shows that patients treated with Inspra (eplerenone) plus standard of care experienced a significant reduction in risk of cardiovascular disease or heart failure hospitalization compared to those treated with standard of care plus a matching placebo.
Today's story goes like this: AstraZeneca has snared Martin Mackay to head up its global R&D organization. Mackay, of course, previously was head of Pfizer PharmaTherapeutics, responsible for Pfizer’s small molecules program and on the company’s executive leadership team.
He led half of Pfizer's R&D engine; the other half was led by Mikael Dolsten, who until today was head of Pfizer BioTherapeutics and Vaccines R&D. Before that Dolsten was head of Wyeth R&D - now he's head of Pfizer's worldwide R&D.
AstraZeneca names Martin Mackay to the newly-created position of president of Global R&D. Mackay previously was head of Pfizer PharmaTherapeutics, responsible for Pfizer’s small molecules program and on the company’s executive leadership team. Pfizer names Mikael Dolsten, previously head of Pfizer BioTherapeutics and Vaccines R&D organization, and before that head of Wyeth R&D, to be president of Pfizer’s worldwide R&D organization.
